Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $922.9K in total
- 3
- 13F holdersQ2 2026, +11 vs. previous quarter
- 183
- 13F valueReported value at the end of Q2 2026
- $1.31B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CGEM, Q2 2026
No superinvestor reported holding CGEM at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Cullinan Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)9:22 AM ET | Sep 8 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $21.57 | −$172.6K | −4.8%158.8K after | 10b5-1 |
| Aug 14, 2026 (view filing)5:00 PM ET | Aug 13 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −30.0K | $20.26 | −$607.8K | −15.6%162.8K after | 10b5-1 |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 6 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $17.82 | −$142.6K | −4.7%162.8K after | 10b5-1 |
| May 6, 2026 (view filing) | May 5 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $14.62 | −$117.0K | −4.6%166.8K after | 2 lots10b5-1 |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $15.68 | −$125.4K | −4.5%170.8K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 25 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −1.78K | $14.14 | −$25.2K | −1.0%174.8K after | 10b5-1 |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −5.35K | $14.31 | −$76.6K | −2.9%176.6K after | 2 lots10b5-1 |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Ahmed NadimPresident and CEO | SSale | −13.5K | $14.47 | −$195.6K | −3.3%390.8K after | |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Jones Jeffrey AlanChief Medical Officer | SSale | −4.58K | $14.47 | −$66.3K | −2.8%160.0K after | |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Sumer Jacquelyn LChief Legal Officer | SSale | −3.60K | $14.47 | −$52.1K | −2.7%128.1K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Cullinan Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MPM Oncology Impact Management LP | 9,731,341 | $177.2M | 10.81% | +2,083,073+27.2% | Added |
| Lynx1 Capital Management LP | 8,963,500 | $163.2M | 18.86% | 00.0% | Unchanged |
| BVF Inc | 5,750,683 | $104.7M | 2.68% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,232,766 | $95.3M | 0.00% | +782,800+17.6% | Added |
| Price T Rowe Associates Inc | 3,825,950 | $69.7M | 0.01% | +1,796,231+88.5% | Added |
| State Street Corp | 3,668,627 | $66.8M | 0.00% | +1,124,512+44.2% | Added |
| Kynam Capital Management, LP | 3,114,132 | $56.7M | 3.13% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,614,066 | $47.6M | 0.00% | +131,032+5.3% | Added |
| RTW Investments, LP | 2,364,347 | $43.1M | 0.37% | +658,387+38.6% | Added |
| Siren, L.L.C. | 1,893,410 | $34.5M | 0.70% | +700,000+58.7% | Added |